PER 0.00% 10.0¢ percheron therapeutics limited

News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-19

  1. 11,041 Posts.
    lightbulb Created with Sketch. 985
    That's one distasteful way of putting it kp. Another way is that they have injected potential growth into a company that was creaking at the foundations. There is potentially a pot of gold now at the foot of the reenergised rainbow.

    Good fortune all holders
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.